{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/622b8f5080a3a00013890f23/66fc9212b01fb2785c49c07d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Wednesday, October 2, 2024","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/622b8f5080a3a00013890f23/1727828443437-b9fc2111-20bc-4b57-8e10-cb8c56419b9e.jpeg?height=200","description":"<p>CVS is rumored to be weighing breaking up its retail and insurance businesses amid investor pressure.&nbsp;Johnson &amp; Johnson is abandoning its controversial 340B drug discount rebate plan. &nbsp;And, The Biden Administration is no longer pursuing its push for greater Medicaid drug price transparency, according to a report. &nbsp;We’ll get that story--and more--coming up on today’s episode of the Gist Healthcare podcast.&nbsp;</p><p><br></p>","author_name":"Gist Healthcare Daily"}